CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...